High Throughput Screening
The High Throughput Screening (HTS) Core Facility at Beckman Research Institute of City of Hope serves as the starting point for drug discovery efforts working in close collaboration with biologists, computational chemists, and medicinal chemists that comprise our Drug Discovery and Structural Biology to bridge the gap between the basic discovery of promising new therapeutic targets and the development of new life-saving, life-improving drugs for patients with cancer and diabetes.
HTS Core occupies over 1000 square feet of laboratory space and facilitates. It offers services of assay development and optimization, high throughput screening, and lead identification and characterization. We currently have a diverse small molecule screening library of over 200,000 compounds available, including selected focused libraries of approved drugs, pharmacologically active molecules and kinase inhibitors among others. The in-house collection of novel and diversified compound libraries is designed for discovering novel drug-like molecules that can be further refined and optimized into new therapeutics. The HTS Core has fully automated HTS system for the screening process, using a centralized scheduling software to integrate and control instruments, including the Echo 650T Acoustic Liquid Dispenser and PerkinElmer EnSight Plate Reader. In addition, the cell-based screening services consist of High Content Screening (HCS) system, kinase activity profiling, and an in-house NCl-60 human cancer cell line assay. These cutting-edge technologies are utilized for drug lead identification and characterization.
Meet the Team
Leadership
Core Staff
David Kwon
Zhe Joe Wang
Contact the Team
Using the Facility
The High Throughput Screening (HTS) Core Facility at Beckman Research Institute of City of Hope occupies over 1000 square feet of laboratory space and facilities. It offers services of assay development and optimization, high throughput screening, and lead identification and characterization. We currently have a diverse small molecule screening library of over 200,000 compounds available, including selected focused libraries of approved drugs, pharmacologically active molecules and kinase inhibitors among others. The in-house collection of novel and diversified compound libraries Is designed for discovering novel drug-like molecules that can be further refined and optimized into new therapeutics.
The HTS Core has a fully automated HTS system for the screening process, using a centralized scheduling software to integrate and control the six instruments, including Echo 650T Acoustic Liquid Dispenser and PerkinElmer EnSight Plate Reader. In addition, the cell-based screening services consist of High Content Screening (HCS) system, kinase activity profiling. and in-house NCl-60 human cancer cell line assay. These cutting-edge technologies are utilized for drug lead identification and characterization. The HTS Core has highly trained and experienced staff, advanced equipment, and a chemical library collection. The combined expertise and technology increase cost-effectiveness and productivity in services. Investigators also benefit from the cumulative skills and experience.
Please contact Dr. Holly Yin at [email protected].
Equipment
The automated pipetting system that consists of an 11-position deck and one thermomixer is under a sterile condition. The instrument utilizes cell-based or immunoassays, real-time PCR and sequencing preparation, serial dilutions, or concentration normalization.
PamStation® 12 is a fully automated instrument using 3 x PamChip 4 microarrays. The kinase profiling array platform monitors kinase activities through phosphotyrosine kinase (PTK) or serine-threonine kinase (STK) peptide substrates containing four positive control ones.
In a given year, City of Hope conducts more than 400 clinical trials enrolling more than 6,000 patients.
Our Publications
Jiménez-Romero, C., Rodriguez, A., & Nam, S.
Könst, Z. A., Szklarski, A. R., Pellegrino, S., Michalak, S. E., Meyer, M., Zanette, C., Cencic, R., Nam, S., Horne, D. A., Pelletier, J., Mobley, D. L., Yusupov, M., & Vanderwal, C. D.
Xu, H. Z., Nam, S., Wu, J., Liu, X., Li, H., Gong, Q., Yin, H., Pillai, R., Querfeld, C., Horne, D., Chan, J., Chen, Y., & Rosen, S. T.
Giannouli, V., Lougiakis, N., Kostakis, I., Pouli, N., Marakos, P., Skaltsounis, L., Horne, D. A., Nam, S., Gioti, K., & Tenta, R.
Michalak, S. E., Nam, S., Kwon, D. M., Horne, D. A, & Vanderwal, C. D.
City of Hope is focused on basic and clinical research in cancer, diabetes and other life-threatening diseases.
